Great HealthWorks, Inc., makers of Omega XL, Report New Independent Study: Omega-3 DHA Protects Against Liver Disease
Oregon State University researchers say omega-3 fatty acid DHA, such as found in Omega XL, has a powerful effect in preventing liver inflammation and fibrosis.
Hollywood, FL (PRWEB) April 28, 2013
One of the first studies to directly compare the effects of omega-3 fatty acids DHA and EPA on liver disease was recently published online in the Journal of Nutrition. The study, supported by the USDA National Institute of Food and Agriculture, as well as the National Institutes of Health, demonstrated that the DHA component of omega-3 fatty acid supplements, such as Omega XL, had a powerful effect, reducing the proteins involved in liver inflammation and fibrosis by more than 65 percent. These liver conditions are common problems among the 67% of Americans who are overweight or obese.
The American Liver Foundation has estimated that about 25 percent of the nation’s population, and 75 percent of those who are obese, have nonalcoholic fatty liver disease. This early-stage liver condition can progress to more serious, even fatal complications, including not only cirrhosis and liver cancer, but also a progressive form of liver disease known as nonalcoholic steatohepatitis (NASH).
NASH is associated with chronic inflammation and oxidative stress, resulting from excess fat storage in the liver. Left untreated, chronic inflammation can eventually lead to fibrosis, cirrhosis, or even liver cancer. About 30-40 percent of people with nonalcoholic fatty liver disease progress to NASH.
According to principal investigator with the Linus Pauling Institute at OSU and a professor in the College of Public Health and Human Sciences, Donald Jump, “many clinical trials are being done with omega-3 fatty acids related to liver disease. Our studies may represent the first to specifically compare the capacity of EPA versus DHA to prevent NASH. It appears that DHA is one of the most valuable for this purpose.”
With omega-3 levels comparable to about 2-4 grams of combined EPA and DHA per day – the same dose used in triglyceride therapies – the researchers noted that the DHA component of the omega-3 supplement was remarkably effective in reducing inflammation, oxidative stress, fibrosis and liver damage.
Omega XL is one of only two Omega 3 supplements sold in the world that contains the patented stabilized marine lipid extract PCSO-524 derived only from the New Zealand green-lipped mussel, with 30 healthy fatty acids including DHA and EPA. Sold in other parts of the world under its sister brand name Lyprinol, Omega XL is manufactured exclusively by Great HealthWorks Inc., and is the most widely available omega-3 fish oil supplement containing the potent PCSO-524 marine lipid extract. To find more information about Omega XL and PCSO-524 visit http://www.OmegaXL.com
SOURCE: Journal of Nutrition, 2013; DOI: 10.3945/jn.112.171322 Oregon State University (2013, February 5). Docosahexaenoic Acid Attenuates Hepatic Inflammation, Oxidative Stress, and Fibrosis without Decreasing Hepatosteatosis in Model of Western Diet-Induced Nonalcoholic Steatohepatitis. http://www.sciencedaily.com/releases/2013/02/130205123758.htm
About Great HealthWorks, Inc.
Great HealthWorks, founded in 2003, is a global manufacturer and distributor of one-of-a-kind, natural products. Great HealthWorks, the makers of Omega XL®, an all-natural, highly purified marine lipid extract from the green-lipped mussel (Perna Canaliculus) known as PCSO-524. This patented marine lipid complex comes exclusively from the pristine waters of the Marlborough Sounds in New Zealand, and contains 30 healthy fatty acids. Great HealthWorks corporate headquarters and distribution center are in Hollywood, Florida. To find out more about Great Health Works, visit http://www.GreatHealthWorks.com. And for more information about the benefits of Omega XL, visit http://www.OmegaXL.com. Join the conversation: http://www.facebook.com/myomegaxl
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/4/prweb10677097.htm